Clinical Trial Update: Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan [Phase 3]

View source ↗

Summary

Phase 3 open-label study of Midazolam Hydrochloride Oromucosal Solution in children with convulsive status epilepticus completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epileptic Seizures
• Nervous System Diseases
• Status Epilepticus

Drugs mentioned

• Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) (Midazolam)

Snippet

Sponsor: Shire | Conditions: Nervous System Diseases | Phase 3 | Status: COMPLETED | Results posted: 2020-07-31